205058-11-3

Usage

Uses

Used in Pharmaceutical Research:
Tert-butyl 4-(2-oxo-4-phenyl-2,3-dihydroimidazol-1-yl)piperidine-1-carboxylate is used as a research compound for its potential pharmacological properties, which may contribute to the development of new drugs. Its unique structure allows it to be a promising candidate for various therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, tert-butyl 4-(2-oxo-4-phenyl-2,3-dihydroimidazol-1-yl)piperidine-1-carboxylate is used as a building block for the synthesis of other compounds with biological activity. Its complex heterocyclic nature makes it a valuable component in creating novel molecules with potential applications in medicine and other industries.
Used in Drug Development:
Tert-butyl 4-(2-oxo-4-phenyl-2,3-dihydroimidazol-1-yl)piperidine-1-carboxylate is used as a precursor in drug development, where its unique structure can be leveraged to create new pharmaceutical agents. Its presence in a compound may enhance the pharmacological profile, leading to improved therapeutic effects.
Used in Chemical Industry:
In the chemical industry, tert-butyl 4-(2-oxo-4-phenyl-2,3-dihydroimidazol-1-yl)piperidine-1-carboxylate may be used as an intermediate in the synthesis of various chemical products, taking advantage of its reactivity and structural features to produce a range of valuable end products.

Upstream product

• 917-61-3 sodium isocyanate 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 70-11-1 α-bromoacetophenone 
• 2142-69-0 2-bromophenyl methyl ketone 

Downstream Products

• 205058-28-2 4-(1,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yl)piperidine 

Relevant academic research and scientific papers

NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS

The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.

CGRP receptor antagonists

The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.

Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N 2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl) -1-piperidinyl]carbonyl]-D-tyrosyl]-L-ly

Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel

Modified aminoacids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4and R11are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

Modified amino acids, pharmaceuticals containing these compounds and method for their production

The present invention relates to modified amino acids of general formula wherein A, Z, X, n, m, R, R2, R3, R4 and R11 are defined as in claims 1 to 5, their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.